SODIAP
ActiveSummary
SODIAP has been active since 1967 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €33.0m and a net result of €411,580. Equity is growing by about 16% per year across the filed financial years. Its solvency ranks better than 56% of 4,961 sector peers (NACE 47, financial year 2025). The computed 12-month bankruptcy probability is 0.3% (very low).
Group and network
Holdings and subsidiaries
34 holdingsHoldings 34
Source for every holding own accounts 2025
- ANTOPHARsubsidiaryEquity €1.2mResult -€87,206100%
- APOTHEEK AMERYsubsidiaryEquity €227,240Result €15,410100%
- APOTHEEK BOSPOORTsubsidiaryEquity €908,418Result €66,552100%
- APOTHEEK BULTYNCKsubsidiaryEquity €1.2mResult €6,589100%
- APOTHEEK DE GROOTEsubsidiaryEquity €1.2mResult -€21,813100%
- Apotheek de LissewegsubsidiaryEquity €1.2mResult €52,938100%
- APOTHEEK JENNEsubsidiaryEquity €1.3mResult €31,345100%
- APOTHEEK SCARPHOUTsubsidiaryEquity €463,825Result €46,725100%
- Apotheek SeurincksubsidiaryEquity €1.8mResult €27,487100%
- APOTHEEK SINT-JOZEFsubsidiaryEquity €1.5mResult €39,635100%
Show 24 more holdings
- APOTHEEK SINT-LODEWIJKsubsidiaryEquity €358,217Result €26,706100%
- C.E. FARMAsubsidiaryEquity €1.2mResult €68,611100%
- DEMAPHARsubsidiaryEquity €875,529Result €21,018100%
- FINDIAPsubsidiaryEquity €913,124Result €83,390100%
- GANDAFARsubsidiaryEquity -€649,097Result -€42,313100%
- HC PharmasubsidiaryEquity -€992,548Result -€235,534100%
- MEDIFARsubsidiaryEquity €351,857Result €43,562100%
- MOUSCRON PHARMAsubsidiaryEquity €2.0mResult €70,063100%
- MRZK PharmasubsidiaryEquity €556,284Result €35,837100%
- NB PHARMAsubsidiaryEquity €573,958Result €56,725100%
- ODRP PharmasubsidiaryEquity €2.0mResult €70,773100%
- PHARMA PLUSsubsidiaryEquity €876,038Result €15,884100%
- PHARMACIE DE GIVRYsubsidiaryEquity €483,944Result €67,222100%
- Pharmacie des BlommessubsidiaryEquity €368,033Result €15,209100%
- PHARMACIE GOULARDsubsidiaryEquity €331,470Result -€22,880100%
- PHARMACIE HELLEBOREsubsidiaryEquity €437,140Result €23,964100%
- PHARMACIE MANDRAGOREsubsidiaryEquity €426,866Result €31,577100%
- SANIFARsubsidiaryEquity €1.1mResult €49,219100%
- SANIMEDsubsidiaryEquity €619,306Result €28,974100%
- SDCsubsidiaryEquity €266,265Result €3,372100%
- STEKENE PHARMAsubsidiaryEquity €485,489Result €51,818100%
- WENDUINE PHARMAsubsidiaryEquity €1.1mResult €74,220100%
- ZICHEM PHARMAsubsidiaryEquity €538,245Result €40,263100%
- Equity €122,621Result €48,00610.21%
According to the 2025 annual accounts of SODIAP and those of the other companies, the acts in the Belgian Official Gazette and the LEI register. Annual accounts state the shareholders that notified the company under article 7:225 of the Code of Companies and Associations and the parent companies that consolidate it. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not include these statements in its annual accounts, or does not have to, is not listed.
Connections & network
1 current directorThe board mandates are listed below; here you explore them as a network.